Valsartan and Amlodipine Tablets
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20223379
Indications:
Treatment of essential hypertension.
This product is used for patients whose blood pressure cannot be adequately controlled by monotherapy.
Administration:
Amlodipine at a dose of 2.5 mg to 10 mg once daily is effective for the treatment of hypertension, and the effective dose of valsartan is 80 mg to 320 mg. In the clinical trials of valsartan and amlodipine tablets once daily, using 5 mg - 10 mg of amlodipine and 80 - 320 mg of valsartan, the antihypertensive effect increases with the increase of the dose.
The adverse reactions of valsartan are usually independent of the dose; the adverse reactions of amlodipine are both dose-dependent (mainly peripheral edema) and dose-independent, and the former is more common than the latter.
For patients whose blood pressure cannot be adequately controlled by monotherapy, this product can be used instead.
Add-on therapy: For patients whose blood pressure cannot be adequately controlled during monotherapy with amlodipine or valsartan, this product can be used for combination therapy.
For patients who experience dose-limiting adverse reactions during monotherapy with amlodipine or valsartan, this product can be used instead. Combine the components of the single drug at a lower dose to achieve blood pressure control. Most of the therapeutic effect can usually be achieved within 2 weeks after starting the medication or changing the dose.
Substitution therapy: For the convenience of administration, patients receiving combination therapy with amlodipine and valsartan can be switched to this product at the same dose for treatment.
Both amlodipine and valsartan can be taken with or without food. It is recommended to take this product with water.
Impairment of liver and kidney function
No dose adjustment is required for patients with mild to moderate renal impairment. Use with caution in patients with severe renal impairment. This product should also be used with caution in patients with liver impairment or biliary obstructive diseases.
Specifications:
80mg/5mg × 14 tablets
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.